Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

Finasteride caused anxiety, depression, and hair shedding for the user, leading them to stop taking it. They are now on Lexapro and Adderall for depression and ADHD, and are considering trying topical Finasteride and Minoxidil.

The user experienced significant hair improvement using 0.5mg Dutasteride and 2.5mg Minoxidil daily for 8 months, with no side effects reported. They noticed thicker, darker hair and increased density, and did not use topical treatments.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

A 24-year-old male is increasing his dutasteride dosage from 0.5mg to 1mg daily due to continued hair thinning despite using finasteride, dutasteride, and topical minoxidil. Another user suggests trying oral minoxidil for potentially better results.

A user experienced significant hair regrowth using finasteride 1 mg daily for two years and gradually introduced dutasteride 0.5 mg daily over four months. They reported no side effects and plan to switch fully to dutasteride due to its cost-effectiveness and potential effectiveness.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Switching from finasteride to dutasteride may be more effective for hair regrowth due to dutasteride's stronger enzyme inhibition, but combining both drugs could enhance results. Some users report better outcomes with dutasteride, while others recommend a gradual transition to prevent potential hair loss.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Dutasteride can significantly increase libido, more so than finasteride. Users reported higher libido when switching from finasteride to dutasteride.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

The user experienced hair recovery using oral dutasteride 0.5 mg and oral minoxidil 5 mg daily, considering increasing dutasteride dosage but concerned about cost and effectiveness. They noted progress and discussed alternatives like hair transplants and other medications.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

A user has been using finasteride for 3 years with good results but wants to switch to dutasteride due to a plateau. They are seeking an online pharmacy that delivers dutasteride to Europe.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The post and conversation are about a user named "Road2Recovery2023" who just got a prescription for 2.5 mg Dutasteride, a treatment for hair loss.

A user reports significant hair shedding and regrowth after increasing their dutasteride dosage to 5mg, alongside using RU58841, minoxidil, and topical finasteride, with no side effects. They recommend high doses of dutasteride, sourced from China, despite concerns about its safety.

A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.